Curlim Receives US Orphan Drug Designation for CLM001 in the Treatment of CMT Disease

A few weeks ago, we announced our Orphan Drug Designation in Europe, and today, we’re proud to share that CURLIM has also obtained Orphan Drug Designation in the United States.

What does this mean?

✔️ It recognizes CLM001, our nanoformulated curcumin drug candidate, as a promising treatment for peripheral neuropathies such as Charcot-Marie-Tooth disease (CMT).

✔️ This designation provides CURLIM with strategic support from the U.S. Food and Drug Administration (FDA), to accelerate the next phases of CLM001’s development.

A proud moment for our team, our partners, and everyone supporting our innovative project.